Oceania Healthcare (OCA) / HY26

PBT scrapes to NZ$1.0m as tax benefit lifts NPAT and capex doubles

Headline swing to profit masks a barely-breakeven pre-tax result, an NZ$8.4m free cash outflow, and leverage still at 14.5x EBITDA.

Release date
21 November 2025
Published
21 April 2026

What changed

Revenue slipped 0.7% to NZ$131.6m, with the mix tilting further to Care Operations (about 78% of group revenue, from 76%) while the "Other" segment contributed no revenue. Underlying EBITDA rose 7.4% to NZ$41.5m. The more striking moves are below EBITDA: profit before tax swung from a NZ$19.5m loss to a NZ$1.0m profit, and NPAT swung from a NZ$17.1m loss to a NZ$4.9m profit. Operating cash flow improved 12.3% to NZ$79.0m, but capex nearly doubled to NZ$53.2m (40.4% of revenue, versus 22.0% prior), producing a disclosed Free Cash Flow from Operations of NZ$8.4m outflow. Gross borrowings fell to NZ$610.1m from NZ$639.0m; cash dropped to NZ$8.6m from NZ$13.0m; implied net debt eased to NZ$601.5m.

What matters

  • PBT is the cleaner read, and it is barely positive. NPAT of NZ$4.9m was lifted above PBT by an NZ$3.9m income tax benefit (effective tax rate of −383% on a near-zero PBT). PBT growth of 105% off a heavy loss base understates how marginal the underlying profit actually is at NZ$1.0m. The headline 129% NPAT swing is not a clean operating signal.
  • Leverage is directionally better but absolutely still heavy. Net debt/EBITDA improved to 14.5x from 16.2x, and management states gearing is back inside target range. Even so, on a land-and-buildings intensive model, the ratio leaves little room for operational setbacks.
  • Capex stepped up materially. At NZ$53.2m, investment in PP&E and investment property development ran almost 2x the prior half's NZ$29.2m. That is the single biggest reason operating cash flow strength did not translate into free cash flow.

Expectations

No quantified guidance, forward work, or FY25 shape context was disclosed, so there is no anchor against which to mark this half. On simple annualisation, HY26 revenue runs at about NZ$263.3m. Management's qualitative tone points to further sustainable improvement in H2 from sales conversion, cost efficiency and working-capital discipline, but the release does not support or refute a specific FY26 EBITDA or NPAT trajectory. What the release does establish is that the profit recovery is real in direction but thin in magnitude at the pre-tax line.

Quality of result

Mixed. The EBITDA improvement of NZ$2.9m looks operationally driven and is supported by segment-level progress in Care Operations (segment result of NZ$13.7m from a NZ$17.6m loss). However, the NPAT print is flattered by a tax benefit, and the cash story is weaker than OCF alone suggests: OCF/EBITDA of 190% is partly a function of the retirement-village resident-loan model rather than pure operating conversion, and once capex is loaded in, free cash flow was NZ$8.4m negative. Receivable days held steady at 28.6, so there is no obvious working-capital assist inflating the earnings line. On balance, the operating improvement is genuine but modest; the statutory profit swing is not a durable measure of progress.

Unresolved

  • What is the split of the NZ$24m capex step-up between maintenance, new village development, and care facility modernisation, and how should it be expected to run through H2?
  • What drove the NZ$3.9m tax benefit on a near-zero PBT, and is the benefit repeatable?
  • "Other" segment revenue disappeared versus NZ$5.3m prior while the segment loss persisted at NZ$16.4m — what was reclassified, and does the corporate-overhead drag normalise?
  • Village Operations segment result of NZ$29.0m on NZ$28.8m of revenue points to non-revenue gains (resales/fair value) in that line; the release does not quantify the recurring versus valuation components.
  • No interim dividend detail, NTA per share, covenant headroom quantification, or forward-work backlog is provided.

This briefing cannot assess unit economics at the village or facility level, the durability of the tax benefit, or how the capex cycle converts into future care-suite and ORA cash inflows, because the release does not disclose those figures.

Key metrics

← Swipe to view more
Metric HY26 HY25 Change
Revenue $131.6m $132.6m -0.7% ↓
EBITDA $41.5m $38.6m +7.4% ↑
Net profit after tax $4.9m −$17.1m +129.0% ↑
Net cash inflow from operating activities $79.0m $70.4m +12.3% ↑
Profit before tax $1.0m −$19.5m +105.2% ↑
Cash and cash equivalents $8.6m $13.0m -33.8% ↓
Total assets $3037.6m $2821.2m +7.7% ↑

Source: annolyse.ai/briefings/oca-hy26

Segment breakdown

← Swipe to view more
Segment Current revenue Prior revenue Current result Mix shift
Care Operations $102.9m $100.5m $13.7m +2.4pp
Village Operations $28.8m $26.8m $29.0m +1.7pp
Other $0m $5.3m −$16.4m -4.0pp

Source: annolyse.ai/briefings/oca-hy26

Analytical metrics

← Swipe to view more
Metric HY26 HY25 Context
Effective tax rate 383.1% n/m (loss period) prior loss period
OCF / EBITDA (cash conversion) 190.4% 182.1% stable
FCF pre-lease −$8.4m
FCF / NPAT -170.0% complementary conversion metric
Capex % revenue 40.4% 22.0%
Capex $53.2m $29.2m +$24.0m
Free cash flow −$8.4m
Debtor days 28.6 28.4 +0.2 days
Trade debtors $20.7m $20.7m −$0.0m
Net debt $601.5m $625.9m −$24.5m
Net debt / EBITDA 14.50x 16.20x Strengthening
Gross borrowings $610.1m $639.0m −$28.9m
ROE (annualised) 0.4% -1.6% Strengthening
Profit from continuing operations $4.9m

Source: annolyse.ai/briefings/oca-hy26


This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Metric context

Trajectory before this result

A compact view of the company's recent revenue and margin path, derived from the same metrics history that powers the company page.

Appendix

Source documents

The filings and announcement documents considered in this briefing.

Current period

1HY26 Interim Report

HY26 / financial report

1HY26 Media Release

HY26 / media release

1HY26 Results Announcement

HY26 / results announcement

Prior comparable period

Subscribe

Want briefings like this for the next reporting season?

Annolyse is being built as a publication product first. Subscribe for the next release.